Role of different germline BRCA mutations in response to platinum-based chemotherapy in patients (pts) with triple-negative breast cancer (TNBC).

e13008Background: TNBC is associated with aggressive behavior and poor prognosis. TNBC is the most common subtype seen in patients with hereditary BRCA associated breast cancer. Because of defects of homologous recombination these tumours may be extremely sensitive to DNA-damaging agents such as platinum. Little is known about influence of different germline BRCA mutations on response to chemotherapy. Previously we have shown that somatic BRCA1 mutations may determine different responses to platinum-based chemotherapy. Now we analyse efficacy of dose-dense schedule of doxorubicin, cisplatin and paclitaxel in pts with hereditary BRCA associated TNBC. Methods: Twenty eightpts with early (cT1-2N0-1M0) and locally advanced (cT2-4N2-3M0) hereditary BRCA associated TNBC were treated with dose-dense combination of doxorubicin, cisplatin and paclitaxel followed by surgery. Mutations distribution is summarized in table 1. Pathological response was evaluated according to the Chevallier classification. Results: Medi...